

Global Premier Biologics Platforms to Enable and Expedite Innovations

*2020 Interim Result
(2269.HK)*

August 2020



WuXi Biologics
Global Solution Provider

Forward-Looking Statements

This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, and our ability to protect our clients’ intellectual property. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section.

Use of Adjusted Financial Measures (Non-IFRS Measures)

To supplement the Group’s condensed consolidated financial statements which are presented in accordance with the IFRS, the Company has provided adjusted net profit, adjusted net profit margin, adjusted EBITDA, adjusted EBITDA margin and adjusted basic and diluted earnings per share as additional financial measures, which are not required by, or presented in accordance with, the IFRS.

The Company believes that the adjusted financial measures are useful for understanding and assessing underlying business performance and operating trends, and that the Company’s management and investors may benefit from referring to these adjusted financial measures in assessing the Group’s financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and/or non-operating items that the Group does not consider indicative of the performance of the Group’s core business. These non-IFRS financial measures, as the management of the Group believes, is widely accepted and adopted in the industry in which the Group is operating in. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRS. Shareholders of the Company and potential investors should not view the adjusted results on a stand-alone basis or as a substitute for results under IFRS. And these non-IFRS financial measures may not be comparable to similarly-titled measures represented by other companies.



01

2020 Interim Results

02

Leading Industry Trends Favoring WuXi Biologics

03

Financial Overview

04

Outlook & Catalysts

05

Appendix

224→286

Integrated Projects YoY

38

New Projects in 1H

15→19

Late Phase Projects YoY

US\$9.5B

Total Backlog

280,000L+

Capacity after 2023

5,694/2,453

Employees/Scientists



1.6→1.9B

Revenue (RMB)

521.5→734.0M

Adj Net Profit (RMB)

21.0%

Revenue YoY Growth

40.7%

Adj Net Profit YoY Growth

40.5%

Gross Profit Margin

37.8%

Adj Net Profit Margin




01


2020 Interim Results

Financial Highlights: Record Revenue and Earnings Growth


Revenue




Gross Profit




Adj EBITDA




Net Profit



Adj Net Profit



Diluted EPS



Available Funds

- Available Funds approx. RMB **5,376** million as at June 30th, 2020
- HK\$ **6,120** million raised in July 2020 to support COVID-19 business and expansion of U.S. facilities
- Available funds approx. RMB **11.0** billion as of July 31st, 2020

LOAN

- Approx. RMB **2,950** million borrowings as at June 30th, 2020
- Maintains bank credit facilities of around RMB **2.5** billion for future cash needs
- Operating cash flow of RMB **431** million, **94.1%** increased YoY

CAPEX

- CAPEX spending amounted to RMB **2.7** billion in 1H 2020
- 2020 CAPEX approximately RMB **5** billion, mainly for capacities expansion in Europe and U.S.

Our Mission

To accelerate and transform the discovery, development and manufacturing of biologics through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide



Our follow the molecule Integrated Solution Model


Our customers' demand for our services increases as their biologics advance through development and ultimately to commercialization, which allows our revenue from each project to grow geometrically as the project advances through the biologics development cycle

Revenue from each project increases with its stages

Biologics Development Process	Typical Duration	Typical Revenue
Pre-IND		
Drug Discovery	2 Years	US\$1.5-2.5 mm (Milestone fee ranges from US\$ 10-100 mm Royalty fee ranges from 3% to 5%)
Pre-Clinical Development	2 Years	US\$4-6 mm
Post-IND		
Early-Phase (Phases I & II) Clinical Development	3 Years	US\$4-6 mm
Late-Phase (Phase III) Clinical Development	3-5 Years	US\$20-50 mm
Commercial Manufacturing	Annually	US\$50-100 mm annually

1H 2020 Pipeline Highlights

- **38** molecules added into pipeline despite pandemic. Total **286** as of June 30, 2020.
- **3** projects added to Phase III
- **4** external projects at different stages transferred in 1H 2020
- US\$ **24.1** million milestone revenue in 1H 2020
- Best **timeline** and **execution** further strengthen market position, fundamentals remains strong




Notes:


1. As of June 30, 2020.

2. The arrows in black are the projects newly added from outside; the arrows in blue are the projects progressing from earlier stage thanks to our follow the molecule strategy; the dashed arrows are terminated projects

Solid Business Progress – Integrated Projects



No. of Integrated Projects ⁽¹⁾



Notes:

1. Integrated projects are defined as projects requiring services for multiple stages during biologics development process
2. Estimated CMO revenue when a biologic drug reaches its peak sales. A biologic drug typically reaches peak sales after a ramp-up period

Strong Backlog Growth Underpins Future Performance

- Total backlog jumped to **US\$9.5 bn**, fundamentals remain strong despite global COVID-19 pandemic

- Service backlog increased **232%** to **US\$5.8 bn** compared with 1H 2019, mainly attributed to **US\$3 bn** long-term vaccine CMO contract and surging COVID-19 projects


- Upcoming potential milestone fees* up to **US\$3.7 bn**, continue to improve margin profile

- Backlog within 3 years maintained high visibility and solid growth in 1H 2020

- Follow the molecule strategy clearly demonstrated effective


- Service Backlog
- Upcoming Potential Milestone Fees*
- Backlog within 3 Years

(US\$ mm)




Follow the Molecule Wins More Trust from Existing Clients

No of Integrated Projects
per Customer



Geographic Snapshot
by Customer No.




- Multiple leading platforms, best execution and track record increase **stickiness** of biologics CDMO
- Follow the molecule with proven track record improved winning rate of new projects from existing clients: **80%+**
- Customer base further diversified , **U.S.** and **China** are still two most important markets

Note:


* Others is the global market, which excludes USA, EU and PRC

Follow the Molecule Drives Customer Growth and Revenue Diversification


Number of Customers Serviced in Each Period ⁽¹⁾




Average Revenue per Project (RMB mm)



Average Revenue per Customer among the Top 10 Customers in Each Period (RMB mm)



Revenue % of the Top 20 and the Top 10 Customers




Note:

1. Number of customers refer to those who incurred revenue during the reporting period.

Robust Global Network Ensures Success of Follow the Molecule



Capacity in Progress (CIP) by Year




Well-positioned for the era of innovative biologics. A robust global network with **280,000L+** capacity to enable our partners over the world.

Global Manufacturing Capacity (280,000L+)

Site #	DS Capacity	GMP Ready	Location	Comments
MFG1	7,500L fed-batch/perfusion	2012	Wuxi	Commercial
MFG2	28,000L fed-batch/2,000L perfusion	2017	Wuxi	Commercial
MFG3	5,200L fed-batch/1,500L perfusion	2018	Shanghai	Clinical/Commercial
MFG4	10,000L fed-batch/CFB	2019	Wuxi	Clinical/Commercial
MFG5	60,000L fed-batch	2021	Wuxi	Commercial
MFG6	6,000L (6 x 1,000L) perfusion	2022	Ireland	Commercial
MFG7	48,000L fed-batch	2022	Ireland	Commercial
MFG8	48,000L fed-batch	2022	Shijiazhuang	Commercial
MFG9	6,000L fed-batch/perfusion	2023	Wuxi	Clinical/Commercial
MFG10	4,000L fed-batch/500L Perfusion	2023	Singapore	Clinical/Commercial
MFG11	8,500L fed-batch	2023	Worcester, MA	Clinical/Commercial
MFG12	48,000L (12 x 4,000L) fed-batch	2023	Chengdu	Clinical/Commercial
MFG13	2x1,000L Viral Manufacturing	2021	Hangzhou	Clinical/Commercial
MFG14	300L/2,000L microbial	2021	Hangzhou	Clinical/Commercial
MFG18	2,000L fed-batch	2021	Cranbury, NJ	Clinical

Business Progress by Regions



North America (NA) still the **most important** market. Growth slowed due to the delay of regulatory inspections and U.S. clinical trials. **12** new projects in U.S. added despite BD challenges. Continued **investments** and **new initiatives** to enable U.S. customers





Chinese market showed an outstanding growth of **43.3%**, due to fast recovery from COVID-19. **19** new projects added during 1H 2020. Public health crisis may spur more **R&D investments** and favorable environment for biologics industry



Rest of the Asia including Korea, Japan, Singapore and Australia showed fastest growth of **61.6%**. Our industry leading **timeline** and **execution** are winning new clients from established markets. One-stop platforms are enabling customers to file IND at the pace of pandemic to fight against COVID-19

Rich Pipeline across All Biologics Formats



114 First-in-class programs



One of **the largest** portfolios of complex proteins consisting of bispecifics, antibody drug conjugates (ADCs) and fusion proteins



More **ADCs** and **Bispecific** projects were added, in line with global biologics innovation trend



All demonstrating **globally** leading technical capabilities

Note:
1. Bispecific Antibody (BsAb) Included both WuXiBody™ projects and non-WuXiBody™ projects

Aggressive Talent Growth Propels Business Success

5,694

Employees as of June 2020.

Expected to reach around 6,600+ by the end of 2020

2,453

One of the largest biologics development teams

8%

Employees holding Ph.D. or equivalent




Dr. William (Bill) Aitchison

SVP, Global Manufacturing

Seasoned Bio-manufacturing Expert

- **30+** years of development and manufacturing experience from global pharmaceutical companies (vaccine, mAbs, proteins and small molecules)
- Strong strategic and operational expertise
- Former SVP at GSK/TESARO and Sanofi Pasteur, VP at Wyeth

Rapid Expansion of Talent Base



1H 2020 Talent retention rate >90%, Key talent: ~94%

**“A pessimist sees the difficulty in every opportunity;
an optimist sees the opportunity in every difficulty”.**

“We are making critical contributions to the treatment and prevention of COVID-19 globally”

**COVID 19 mAb
Work in Progress**

- **10+** Programs from US/EU/China signed
- **~US\$320 mm** contract including **US\$116 mm** from VIR/GSK for large scale DS manufacturing of COVID-19 mAbs
- **~70%** winning rate YTD




**COVID 19 mAb
Potential Contracts**

- **80+** inquiries
- **24** companies and **27** programs in active negotiations




From One Year to 47 Days: Capturing COVID-19 Opportunities



From lead to contract execution and project kick off in 47 days!
From Lead to IND potentially in 5 months

COVID-19 Neutralization Mab Development at the Speed of Light



Innovative Remote Solutions Developed within One Month

Common Technical Solutions

- Video Conference
- Live Tour



Specific Technologies


Remote Due Diligence

- Video on Demands
- Project Specific Discussions



Remote GMP Audit

- Audit Doc Online Review
- Audit Paper Live Review



Remote Person-in-Plant

- Surveillance Camera
- Video Transmission Box
- Access to Process Historian



COVID-19 Impact Diminished - Multiple Catalysts Ahead



Task Force led by CEO and Business Continuity Plan (BCP) demonstrated effective. No projects delayed. 100% staff back to work. None of 5,694 staff infected




- FDA pre-approval inspection scheduled in Q1 2020 would likely be deferred to late 2020 delaying CMO revenue
- 1 month loss of operation



- Among the 1st tier global CDMO enabling 10+ COVID-19 programs
- 3 INDs filed for COVID-19 projects in 1H 2020

- Work at the pace of pandemic: expect to file IND for neutralizing antibody within 3-5 months
- Playing a key role in the global fight against COVID-19 with best-in-industry timeline and premier technology platforms



Fundamentals of business remain very strong. Despite the temporary impact of COVID-19 in 1H, 2020 will still witness significant growth

Business Outlook on COVID-19

Minus

- Limited interactions with clients: implemented e-visit, e-Audit, a-PIP systems
- Delaying milestone revenue, FDA inspection and manufacturing lots: ~US\$100 mm revenue delay to 2021

Plus

- Improved binding with clients: more recognition
- COVID-19 programs: **US\$80+ mm** revenue in 2020 and **US\$150+ mm** 2021
- More large pharma expanding collaborations due to COVID-19

Improved Client Stickiness due to COVID-19

Rapid responses and sound BCP plan: no milestone missed for any integrated projects, winning acclamations from clients all over the world

Completed **3** process validation/PPQ campaigns during COVID-19 outbreak: tenacity and resilience demonstrated


Strong execution fully manifested during COVID-19

Shared COVID-19 fighting best practice with the global clients

Purchased masks from China to support global clients



Global ESG Standard: AA MSCI Rating



- Strictly comply with the Environmental Protection Law and other EHS regulations
- MSCI **AA ESG** rating and **BEST ESG** awards of Institutional Investor (All-Asia) in 2020
- Disposable bioreactors consume **90%** less water and energy and eliminate **100%** detergent during cGMP production
- **Least** resources consumed, **lower** emissions and less waste produced



- Hazardous waste disposable optimize
- Boiler low nitrogen discharge, 2/3 NOx discharge reduction
- NHMC (Non-Methane Hydrocarbons) emission reduction



- Re-use of waste water to cooling system
- waste water to be treated can be reused for landscape and greening




Leading Industry Trends Favoring WuXi Biologics

Bispecifics May Be the Next Wave - WuXiBody™



Leading Edge
Technology


Empower to discover best
or first-in-class molecules




WuXiBody™ Bispecific
Antibody Technology Platform



Out-licensed Projects for WuXiBody™





WuXiBody™ Development Progress




- Strong adoption of WuXiBody™ technology since its launch in 2H 2018
- 7 projects moving to preclinical to demonstrate state-of-the-art technology
- 2-3 WuXiBody™ projects will be expected to file IND in 2020

ADC Drives Additional Growth

WuXi Biologics ADCs
Manufacturing by 1H 2020





ADCs Development
Progress



Selected Global ADCs Partners

Manufacture 35 g/L Process for a Bispecific: State-of-the-Art



“


- 20+ WuXiUP projects
- 2 BLAs targeted

”

WuXi Bio Speed Expedites and Enables Our Partners: 12 Months!


Utilizing sophisticated technology platforms and providing integrated services for ALL the CMC activities from DNA to IND filing in the shortest timeline globally

- Faster First In Human
- Faster approval
- Reducing product development costs and save expenses



Disposable Manufacturing as Disruptive Technology

Conventional Bioreactors



Single-Use Bioreactors

- ☑ No cleaning and sterilization
- ☑ Simple design & operation
- ☑ Saves time and resources
- ☑ Minimal utilities
- ☑ Less maintenance and repair
- ☑ Simple qualification & validation
- ☑ Low contamination risk
- ☑ Less capital investment

VS

HyClone Single-Use Bioreactor (SUB)

Permanent Support Vessel (50 and 250L)



Single-Use Bioreactor BPC

HyClone

- Global leader and pioneer of using disposable manufacturing technology which is now being adopted by the global industry
- Largest global network of **18** facilities exclusively using disposables bioreactors, no stainless bioreactors
- **700+** batches manufactured at **98%** success rate
- Comparable COGS with 10,000L+ with **scale-out** strategy (achieved as low as US\$80 per gram)
- **Less** CAPEX, faster in building facilities and comparable COGS resulting in higher ROI (MFG1 10-year ROI 51% realized, MFG2 35%, MFG3 50% expected)




03


Financial Overview

Financial Performance


Revenue




Adjusted EBITDA (1)



Gross Profit



Adjusted Net Profit (2)



Notes:

1. Adjusted EBITDA represents net profit before (i) interest expenses, income tax expenses, listing expenses and (ii) certain non-cash expenses, consisting of share-based compensation, amortization and depreciation and (iii) foreign exchange (gains)/losses


2. Adjusted net profit excludes the share-based compensation expenses, Listing expenses and foreign exchange (gains)/losses

3. Refers to foreign exchange (gains)/losses

Financial Performance


Net Profit

RMB mm




Profit Attributable to Owners of the Company

RMB mm




Diluted EPS

RMB




Adjusted Diluted EPS


RMB




Robust Growth Across All Geographic Markets (1)



1H 2020 Revenue (RMB)



1H 2019 Revenue (RMB)




Notes:

1. Geographic breakdown by client headquarters
2. Rest of the world primarily includes Singapore, Japan, South Korea, Australia and Israel.

Gross Margin Snapshot


Cost of Services as % of Revenue



Notes:

1. Adjusted gross margin excludes the share-based compensation expenses

Despite Launch of New Sites Excellent Gross Profit Margin Achieved in 1H 2020





04

Outlook & Catalysts

Continuing to Gain Market Share to Support Robust Growth

Cutting Edge Technology

- WuXiBody™ bispecific (universal, 6-18 months of time-saving, minimal CMC issue)
- ADC (greatly enhanced DAR4, dedicated MFG sites, 10+ IND filings)
- WuXia cell line (robust cell line with proven track record)
- WuXiUP continuous manufacturing platform (30-50g/L titer, 10+x)

Best Timeline

IND Filing Timeline

- Industry average: 18-24 months
- WuXi Bio target: 15 reduced to 12 months now!
- WuXi Bio record: 7 months, <3 months for coronavirus related projects

Excellent Track Record

- 100% projects delivered
- No customer transfer out
- Excellent customer satisfaction and high recognition


Unparalleled Capacity

- Capacity for IND enabling projects increased from 60 per year to 80+
- Late phase capacity increased from 5 BLAs to 7 per year
- One of the largest scientist team: ~2,500
- Largest capacity using single-use bioreactor: 280,000L after 2023

Six Pillars Underpins WuXi Biologics Sustainable Growth


- 1** Excellent IP protection (vs China and India competitors)
- 2** FDA and EMA accepted quality system: only company in China, top 10 among global CDMOs
- 3** State-of-art technology platform: comparable to large pharma
- 4** Superb execution won trust from global clients
- 5** World-class talent: 500+ senior scientists, 1,000+ young scientists per year
- 6** Strong financials: around US\$1.6 bn cash

Multiple Engines Support Sustainable High Growth




Conclusion: Business Momentum Remains Strong

In 2020, we will enable our global partners to work at home, enlarge more collaborations with our improved timeline and increased capacities, improve efficiency of our operations and continue to accelerate global footprint to achieve outstanding performance



2H 2020 Key Milestones and Catalysts



- 1st IND filing of WuXiBody™
- 7 INDs filing for COVID-19 mAbs
- Potential COVID-19 vaccine deals
- FDA pre-license inspection at MFG2

- US BLA approval
- 1st Chinese BLA approval
- DP7 operational in Germany





05

Appendix





A. Financial Summary

First Half 2020 Financial Summary

(RMB million)	1H 2020	1H 2019	Change
Revenue	1,944.1	1,607.1	21.0%
Cost of Sales and Services	(1,156.8)	(936.1)	
Gross Profit	787.3	671.0	17.3%
Other Income	148.4	123.8	
Other Gains and Losses	225.7	16.3	
Impairment Losses under Expected Credit Loss Model, Net of Reversal	(56.6)	(9.6)	
Selling and Marketing Expenses	(48.5)	(26.3)	
Administrative Expenses	(203.4)	(149.7)	
Research and Development Expenses	(124.4)	(109.1)	
Share of (Loss) Profit of an Associate	(1.1)	0.3	
Financial Cost	(22.4)	(4.6)	
Profit before Tax	705.1	512.0	37.7%
Income Tax Credit (Expenses)	25.6	(62.6)	
Profit for the Period	730.7	449.5	62.6%
Earnings per Share – Basic (RMB)	0.57	0.37	
Earnings per Share – Diluted (RMB)	0.53	0.34	

Note:

1. Results may not foot due to rounding

Reconciliation for Adjusted Net Profit and Adjusted EBITDA

(RMB million)	1H 2020	1H 2019	Change
<u>Adjusted Net Profit Reconciliation</u>			
Net Profit	730.7	449.5	
Share-based Compensation	126.4	81.3	
Foreign Exchange Gain	(123.1)	(9.3)	
Adjusted Net Profit	734.0	521.5	40.7%
<u>Adjusted EBITDA Reconciliation</u>			
EBITDA	941.4	675.4	
Share-based Compensation	126.4	81.3	
Foreign Exchange Gain	(123.1)	(9.3)	
Adjusted EBITDA	944.7	747.4	26.4%

Note:

1. Results may not foot due to rounding



B. WuXi Bio's Technologies and Capabilities

State-of-the-Art Technology Differentiates WuXi Bio

1 WuXiBody™ Bispecific Platform

- Combine any two antibodies and assemble into bispecifics
- Easy to express, no aggregation or mispairing, can be developed **6-18** months faster and much lower COGS than competitor platforms
- Support **50+** projects per year which attracts downstream services

2 Transgenic Animal For mAbs Discovery

- Access to OMT's state-of-the-art transgenic animal technology to develop fully human antibodies with high quality, specificity, expression, solubility and stability
- Proven technology platform used by **20+** other global companies
- Support 50+ projects per year with potential downstream services

3 Antibody Drug Conjugate Discovery

- Integrate our in-house antibody discovery, toxin and linker to deliver the ideal lead ADC molecules
- Greatly simplify ADC drug development by providing a one-stop shop
- **30+** ongoing projects with ADC discovery services with potential downstream service

4 WuXia Cell Line Platform

- Our own proprietary cell line paired with our own proprietary algorithm is more cost-effective, more efficient and yields better results
- License know-how generated during cell line engineering and development process to the customer in exchange for a license fee and future royalty payments
- Developed **305+** CHO-K1 cell lines total for therapeutic protein purpose

5 Disposable Manufacturing Technology

- No cleaning and sterilization required for disposable bioreactors that use pre-radiated plastic bags as the production vessel in a stainless holder
- A facility using disposable bioreactors can be built 12 to 18 months faster with **30% to 50%** less investment, and can produce 5% to 15% more batches of products with a higher success rate compared to traditional stainless steel bioreactors

6 WuXiUP Continuous Manufacturing Platform

- The next generation biologic manufacturing solution to accelerate biologics development and manufacturing as well as to improve the affordability of biologics
- **30-50g/L** titer, **10+x**
- Enabling 2,000L disposable bioreactors to comparable productivity as traditional SS tank through WuXiUP

Globally Recognized Technology with 39 IP Applications

WuXi 无瑕
4 patent applications
1 in-licensed patent

Proprietary High Titer Production
CHO K1 Cell Line Development
Platform

Antibody Drug Physic-chemical
Structure and Biological Activity
Analysis Platform

WuXi Bio **DAR4**
4 patent applications

Comprehensive ADCs
Development Platform

1

2

3

4

5

6

Proprietary Universal Bispecific
Antibody Platform


Proprietary Ultra-high Productivity
Continuous Perfusion Cell Culture
Platform

Antibody Drug Purification and
Formulation Development
Platform

More.....

WuXiBody™ Bispecific
Antibody Technology Platform
24 patent applications

无上
WuXiUP
6 patent applications




Global Partners Continue to Expand

300+ global partners including **16** of the 20 largest pharmaceutical companies in the world and **28** of the 50 largest pharmaceutical companies in China



Global Dual Sourcing within WuXi Bio: Robust Supply Chain



Global Dual Sourcing within WuXi Bio

- World-class capabilities, expanding capacities, excellent track record and superb execution securing more projects globally than other players
- Biologics projects are **sticky**, securing early stage projects to ensure high likelihood of continuing to commercialization—Follow the molecule
- Our “**on-demand global capacity planning**” and “**global dual sourcing within WuXi Bio**” fulfill our global customers’ rapid growing demand
- Follow the molecule strategy taking on effect: more integrated projects moving to CMO stage starting from 2020
- **Two** Programs from DNA to BLA achieved

High-Impact Innovation to Enable Customers' Success

WuXiBody™ Bispecific Platform

- Universal
- **6-18** months of time-saving
- Minimal CMC issue
- More strategic partnerships with customers



WuXia Cell Line

- Robust cell line with proven track record
- Enabling **60** Integrated Projects Per Year
- **40+** ongoing clinical projects in U.S., EU and China



WuXiUP Continuous Manufacturing Platform

- **30-50g/L** titer, 10+x
- Achieving ultra-high productivity
- Enabling **2,000L** disposable bioreactors to **comparable productivity** as 20,000L traditional SS tank



Discovery

Development

Manufacturing

Innovation of next growth cycle in biologics

Leading Edge Technology of WuXiBody™

DIFFERENTIATION

- **Universal:** almost any mAb sequence can be used to build bispecifics
- **Flexibility:** bi/tri/tetra valency based on biology

SPEED

Minimal CMC challenges: no expression, aggregation or purification challenges – Save **6-18** months of development time

QUALITY

- Expected **low immunogenicity:** natural sequence without complicated engineering
- Typical in vivo **half-life**, longer than typical bispecifics

WuXiBody™ Platform

A new era in bispecifics



abl**bio**
medicine for a better life

AC Immune

正大天晴
CHIATAI TIANQING

安科生物
ANKEBIO

天境生物
I-MAB BIOPHARMA

OXFORD
BioTherapeutics


Brii

almirall


More...

WuXi Bio's Patented ADC Conjugation Technologies - Greatly Enhanced DAR4, Significantly Improved Therapeutic Windows


ADC produced with conventional method, natural DAR distribution




ADC produced with WuXi Biologics' IP for native IgG1




ADC produced with WuXi Biologics' IP for engineered IgG1/4




mAb in clinic: Trastuzumab



Rituximab




Drug-Antibody Ratio (DAR) Greatly Affects Efficacy And Safety of ADC



Clinical Cancer Research. 10, 7063-7070 (2004)
Bioconjugate Chem. 25, 656-664 (2014)

WuXiUP to Expedite Product Launch and Reduce Manufacturing Cost



WuXi Vaccines: Appointed Mr. Jian DONG as CEO



Mr. Jian DONG
CEO
WuXi Vaccines

- **30+ years of bio-manufacturing experience**
- **SVP at WuXi Biologics, head of Wuxi bio-manufacturing and oversea global engineering**
- **Formerly Deputy General Manager at Unilab Bioscience, Vice President at Celgen, and Senior Process Engineer at Eli Lilly**
- **Extensive experience in vaccine manufacturing and facility qualification**
- **Strong tech transfer and large scale commercial production expertise**

“ We are confident that Jian will lead the company to establish a global high-quality system with outstanding vaccine CDMO capabilities. With a vision to accelerate and transform vaccine development and production, WuXi Vaccines will make substantial contributions to expedite vaccine development and ensure a robust supply chain.”



Dr. Chris CHEN
Chairman
WuXi Vaccines

WuXi Bio Speed Manifested Again in Ireland

- “ • Nov. 2019: announced **US\$240 mm** investment
- Feb. 2020: signed the first **US\$3 bn** contract
- Aug. 2020: QC lab ready, steel erected
- Negotiating **4** potential COVID-19 vaccines' manufacturing contracts ”



WuXi Bio Vision

“Every drug can be made and every disease can be treated” by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry

